LUNG CANCER

LP-300, a novel small molecule, shows promise as a potential breakthrough treatment for advanced non–small cell lung cancer in never smokers.

Suresh S. Ramalingam, MD, discussed the practice-changing findings and implications of the phase 3 LAURA study investigating osimertinib for the treatment of patients with EGFR-mutated non–small cell lung cancer.

During a Case-Based Roundtable® event, John V. Heymach, MD, PhD, talked with event participants about adverse events they have observed in their patients after using immune checkpoint inhibitors in the second article of a 2-part series.

While sacituzumab govitecan did not statistically improve overall survival vs docetaxel, there was a numerical improvement observed in patients with non–small cell lung cancer.

Nicolas Girard, MD, PhD, discussed findings from the PALOMA-2 study investigating subcutaneous vs intravenous amivantamab plus lazertinib for previously untreated, EGFR-mutant non–small cell lung cancer.

SenoVax, a novel senolytic immunotherapy for NSCLC, has been submitted as an investigational new drug application to the FDA, initiating a clinical trial to test its efficacy.

The FDA’s Oncologic Drugs Advisory Committee convened to assess the need for rigorous trial designs evaluating perioperative regimens in resectable non–small cell lung cancer.

A phase 2 trial shows that THIO, a new investigational drug, combined with cemiplimab, may be an effective and well-tolerated treatment for patients with advanced non–small cell lung cancer who have exhausted other options.

The first pretreated patient with HER2-altered non–small cell lung cancer was dosed with NVL-330, a novel HER2-selective inhibitor, in the HEROEX-1 trial.

Ajaz M. Khan, MD, MBA, CPE, provides his insights into the novel biomarkers and up-front immunotherapies that are changing the landscape of treatment for patients with lung cancer.

During a Case-Based Roundtable® event, John V. Heymach, MD, PhD, discusses the use of immunotherapy combinations based on patients PD-L1 expression in the first article of a 2-part series.

In an interview, Aakash Desai, MD, MPH, discussed significant lung cancer treatment advancements that were highlighted at ASCO 2024.

Jessica Paulus, ScD, discussed a study investigating real-world trends in lung cancer staging among community oncology practices.

During a Case-Based Roundtable® event, Yasir Y. Elamin, MD, discussed with participants how they select treatment for a patient with ALK+ non–small cell lung cancer and brain metastases in the first article of a 2-part series.

Narjust Florez, MD, shared insights into emerging issues seen for young patients with lung cancer facing fertility and pregnancy and the urgent need for tailored guidelines and research.

Encouraging trends were seen with osimertinib and platinum-pemetrexed chemotherapy in patients with EGFR-mutated advanced non–small cell lung cancer in the phase 3 FLAURA2 study.

Atezolizumab can be given subcutaneously and it is a preferred method of delivery by patients with non–small cell lung cancer, according to results from the phase 2 IMscin002 trial.

Amivantamab plus chemotherapy significantly prolonged progression-free survival in patients with EGFR-mutant advanced non–small cell lung cancer.

A self-taught AI tool that accurately diagnoses adenocarcinoma and predicts cancer recurrence has been developed and has shown to outperform traditional methods.

Minesh Mehta, MD, discusses positive findings from the phase 3 METIS trial investigating TTFields therapy for brain metastases in NSCLC.

The METIS trial of tumor treating fields for the treatment of brain metastases in patients with non–small cell lung cancer met its primary end point, showing a statistically significant improvement in time to intracranial progression.

The combination of nivolumab and ipilimumab with chemotherapy shows significant long-term survival benefits in metastatic NSCLC, irrespective of PD-L1 expression or histology, as per updated 5-year data.

The combination of the adenovirus CAN-2409 and valacyclovir with continued immune checkpoint inhibitor therapy demonstrated favorable tolerability and induced a positive immune response.

Perioperative nivolumab led to a significant improvement in event-free survival in the phase 3 CheckMate 77T trial in patients with stage III N2 and stage III non-N2 non–small cell lung cancer.

During a Case-Based Roundtable® event, Julia Rotow, MD, continued a discussion on how biomarker testing for patients with non–small cell lung cancer impacts treatment decisions in the second article of a 2-part series.

Datopotamab deruxtecan was efficacious among patients with non-small cell lung cancer and baseline brain metastases who harbor actionable genomic alterations, according to an exploratory analysis of the phase 2 TROPION-Lung05 trial.

Patients with ROS1-positive non–small cell lung cancer responded to the next-generation inhibitor taletrectinib with acceptable toxicity.

Recent data shows that telehealth is comparable to quality of life to in-person visits for patients with advanced non–small cell lung cancer.

Osimertinib given after chemoradiation in patients with advanced non–small cell lung cancer harboring a EGFR mutation showed significant benefits.

Suresh Ramalingam, MD, principal investigator of the phase 3 LAURA trial, explains the study's evaluation of osimertinib in EGFR-mutated non-small cell lung cancer.